Literature DB >> 18410898

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia.

Mehdi Hamadani1, Farrukh T Awan, Edward A Copelan.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment of many patients with acute myeloid leukemia (AML). Despite extensive study, the appropriate role and timing of allogeneic and autologous transplantation in AML are poorly defined. This review critically analyzes the extensive literature, focusing on the recent advances, and provides practical recommendations for the use of HSCT in AML.

Entities:  

Mesh：

Year:  2008        PMID： 18410898     DOI： 10.1016/j.bbmt.2008.02.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  14 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

3.  The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.

Authors:  Kambiz Bagheri; Kamran Alimoghadam; Ali Akbar Pourfathollah; Zuhair Muhammad Hassan; Jamshid Hajati; Seyyed Mohammad Moazzeni
Journal:  Pathol Oncol Res       Date:  2008-09-20       Impact factor: 3.201

4.  Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.

Authors:  Mehdi Hamadani; Michael Craig; Gary S Phillips; Jame Abraham; William Tse; Aaron Cumpston; Laura Gibson; Scot C Remick; Pamela Bunner; Sonia Leadmon; Patrick Elder; Craig Hofmeister; Sam Penza; Yvonne Efebera; Leslie Andritsos; Ramiro Garzon; Don M Benson; William Blum; Steven M Devine
Journal:  Hematol Oncol       Date:  2011-02-28       Impact factor: 5.271

5.  Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.

Authors:  Khoan Vu; Shivaprasad Manjappa; John F DiPersio; Feng Gao; Peter Westervelt; Ravi Vij; Keith E Stockerl-Goldstein; Geoffrey L Uy; Camille N Abboud; Mark A Schroeder; Todd A Fehniger; Amanda F Cashen; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

6.  The evolving role of statins in hematopoietic stem and progenitor cell transplantation.

Authors:  Mehdi Hamadani; Michael D Craig; Laura F Gibson; Scot C Remick
Journal:  Am J Blood Res       Date:  2011-06-01

7.  Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

Authors:  U Popat; M J de Lima; R M Saliba; P Anderlini; B S Andersson; A M Alousi; C Hosing; Y Nieto; S Parmar; I F Khouri; P Kebriaei; M Qazilbash; R E Champlin; S A Giralt
Journal:  Bone Marrow Transplant       Date:  2011-03-21       Impact factor: 5.483

8.  Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation.

Authors:  Shinichiro Morishita; Katsuji Kaida; Kazuhiro Ikegame; Satoshi Yoshihara; Kyoko Taniguchi; Masaya Okada; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2011-04-09       Impact factor: 3.603

Review 9.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

10.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.